红细胞生成素治疗尿毒症血透患者贫血对心血管系统的影响  

Cardiovascular Consequences of Correction of the Anemia of Renal Failure with Erythropoietin

作　　者：江德文[1] 高丽真[1] 叶琼[1] 郑舒亮[1] 

机构地区：[1]福建医科大学附属第一医院肾内科

出　　处：《福建医科大学学报》1997年第1期62-64,共3页Journal of Fujian Medical University

摘　　要：目的研究基因重组人红细胞生成素（Ｅｐｏ）替代治疗慢性肾功能衰竭（ＣＲＦ）患者贫血对心血管系统的影响。方法２２例ＣＲＦ血液透析贫血患者，使用Ｅｐｏ（４．６±１．２月）前后应用二维彩色心动超声图及放免法测定血管活性物质肾素（ＰＲＡ）、血管紧张素Ⅱ（ＡｎｇⅡ）、醛固酮（Ａｌｄ）及血液动力学变化。结果随着贫血的纠正，ＰＲＡ，ＡｎｇⅡ和Ａｌｄ无明显变化。心率、心排出量、心排指量均显著降低（Ｐ＜０．０５）；总外周血管阻力显著增高（Ｐ＜０．０１）。结论ＣＲＦ患者Ｅｐｏ治疗后其心脏收缩功能改善。Objective\ To study the effect of recombinant human erythropoietin(rHuEpo)on cardiovascular systems in the patients with chronic renal failure(CRF).\ Methods\ The plasma renin activity(PRA),angiotensin Ⅱ(AngⅡ) and aldosterone (Ald) were measured using redioimmunoassay,and the cardiovascular hemodynamics was assessed by echocardiography in 22 hemodialysis patients with anemia caused by CRF before and after rHuEpo treatment for 4.6±1.2 months.\ Results\ There was no significant difference in PRA,AngⅡ and Ald with the amelioration of anemia.\ The heart rate(HR),cardiac output and cardiac index were decreased slightly,while total vascular resistance raised markedly after the treatment.\ Conclution\ Correction of the anemia in hemodialysis patients with CRF using rHuEpo improved global ventericular systolic function.

关 键 词：基因重组人红细胞生成素 尿毒症 贫血 心血管系统 

分 类 号：R556.05[医药卫生—血液循环系统疾病] R977[医药卫生—内科学]